Paraxel Receives BioSingapore Award for Best Performing CRO
Boston, MA, March 23, 2009 – PAREXEL International Corporation (NASDAQ:PRXL), a leading global biopharmaceutical services provider, today announced that the Company has received the Best Performing Clinical Research Organization (CRO) Award from BioSingapore, an industry association for life sciences businesses encouraged by the Economic Development Board of Singapore. The award was presented to PAREXEL at the BioSingapore Asia/Pacific Biotechnology Awards 2009 Gala Dinner held March 17, 2009 during the BioMedical Asia Conference in Singapore. BioSingapore's Awards celebrate the contributions of companies and individuals in the life sciences industry to advancing the scientific enterprise in the Asia/Pacific region.
According to Michael Entzeroth, Ph.D., Chairman of BioSingapore, "The BioSingapore Award for Best Performing CRO, which was reviewed by an independent panel of peer judges, honors PAREXEL for its focus on supporting clinical development throughout the Asia/Pacific region. PAREXEL is recognized for the broad spectrum of services provided by the Company, the competitive edge it has created in this geography, and its international reputation for speed and high quality. BioSingapore is pleased to commend PAREXEL for its overall outstanding performance and contributions to advancing the clinical research environment in the Asia/Pacific region.”
"PAREXEL is honored to be chosen as the Best Performing CRO by BioSingapore,” said Mark A. Goldberg, M.D., Chief Operating Officer of
PAREXEL International. "PAREXEL has had a long-term commitment to providing high quality clinical development services in the Asia/Pacific region. As outsourced clinical research experiences accelerated growth in this geography, we look forward to continuing to provide both global capabilities and local expertise to meet client needs in developing safe and efficacious treatments. This achievement would not have been possible without the dedication of our talented employees and the ongoing support of our valued clients in the region.”
For more information about PAREXEL's capabilities in the Asia/Pacific region visit http://www.parexel.com/emerging-regions.html. More information about BioSingapore can be found at http://www.biosingapore.org.sg/.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
